Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 7/20 | 0.57 |
| ▸ | ACE | P12821 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | ECE1 | P42892 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | NPEPPS | P55786 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | CPA3 | P15088 | 1/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7271417 | 0.90 | MME (0.65) | MMEACEALDH1A1HPGDMAPK1 | |
| SCHEMBL9724784 | 0.85 | PKM (0.62) | MMEACEALDH1A1HPGDMAPK1 | |
| SCHEMBL9396607 | 0.84 | CPA3 (0.43) | MMEACEALDH1A1HPGDMAPK1 | |
| SCHEMBL9724811 | 0.84 | MME (0.65) | MMEACEALDH1A1HPGDMAPK1 | |
| SCHEMBL9724992 | 0.83 | MME (0.57) | MMEACEALDH1A1HPGDMAPK1 | |
| SCHEMBL9724827 | 0.83 | MEN1 (0.59) | MMEACEALDH1A1HPGDMAPK1 | |
| SCHEMBL390864 | 0.83 | MME (0.57) | MMEACEALDH1A1HPGDMAPK1 | |
| SCHEMBL6167389 | 0.82 | ECE1 (0.51) | MMEACEALDH1A1HPGDMAPK1 | |
| SCHEMBL6169635 | 0.82 | MME (0.50) | MMEACEALDH1A1HPGDMAPK1 | |
| SCHEMBL10800305 | 0.82 | ALDH1A1 (0.67) | MMEACEALDH1A1HPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5403824-A | Administering a opioid, opioid-degrading enzyme inhibitor or enkephalin secretagogues or mixtures thereof; side effect reduction | THE PROCTER & GAMBLE COMPANY (US) | 1995-04-04 | — | — | US | claimed |
| WO-1994021242-A1 | METHODS FOR THE TREATMENT OF OSTEOPOROSIS | THE PROCTER & GAMBLE COMPANY (US) | 1994-09-29 | — | — | WO | claimed |
| US-20240327360-A1 | CRYSTALLINE (2S,4R)-5-(5'-CHLORO-2'-FLUORO-[1,1'-BIPHENYL]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HYDROXYISOXAZOLE-5-CARBOXAMIDO)-2-METHYLPENTANOIC ACID AND USES THEREOF | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2024-10-03 | — | — | US | disclosed |
| US-20230330028-A1 | PROCESS FOR THE PREPARATION OF DRUG DELIVERY SYSTEMS HAVING A TESTOSTERONE COMPOUND PRESENT IN AN OUTER LAYER OR PART, AS WELL AS SUCH DRUG DELIVERY SYSTEMS | EB IP HYBRITABS B.V. (NL) | 2023-10-19 | — | — | US | disclosed |
| US-20200306195-A1 | PROCESS FOR THE PREPARATION OF DRUG DELIVERY SYSTEMS HAVING A TESTOSTERONE COMPOUND PRESENT IN AN OUTER LAYER OR PART, AS WELL AS SUCH DRUG DELIVERY SYSTEMS | EB IP HYBRITABS B.V. (NL) | 2020-10-01 | — | — | US | disclosed |
| US-7427498-B2 | Composition, methods and reagents for the synthesis of a soluble form of human PHEX | UNIVERSITE DE MONTREAL (CA) | 2008-09-23 | — | — | US | disclosed |
| US-20040234518-A1 | Composition, methods and reagents for the synthesis of a soluble form of human PHEX | UNIVERSITE DE MONTREAL (CA) | 2004-11-25 | — | — | US | disclosed |
| US-5403824-A | Administering a opioid, opioid-degrading enzyme inhibitor or enkephalin secretagogues or mixtures thereof; side effect reduction | THE PROCTER & GAMBLE COMPANY (US) | 1995-04-04 | — | — | US | disclosed |
| WO-1994021242-A1 | METHODS FOR THE TREATMENT OF OSTEOPOROSIS | THE PROCTER & GAMBLE COMPANY (US) | 1994-09-29 | — | — | WO | disclosed |
| US-5098934-A | Enkephalinase inhibitors as analgesics or anticargcinogenic agents | ROUSSEL UCLAF (FR) | 1992-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040234518-A1 | Composition, methods and reagents for the synthesis of a soluble form of human PHEX | TPX2, PHPT1, BMX | MME 353/4885ACE 1864/4885ALDH1A1 4361/4885 |
| US-20240327360-A1 | CRYSTALLINE (2S,4R)-5-(5'-CHLORO-2'-FLUORO-[1,1'-BIPHENYL]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HYDROXYISOXAZOLE-5-CARBOXAMIDO)-2-METHYLPENTANOIC ACID AND USES THEREOF | MME, CTSC, REN | MME 1/4885ACE 4/4885ALDH1A1 3055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.